文献速递淋巴瘤造血干细胞移植与细胞治疗

Polatuzumab vedotin 作为复发或难治性大B细胞淋巴瘤的挽救与桥接治疗:德国真实世界研究

Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
PubMed 文献 · Blood Adv · 2021-01-01

挽救组最佳总缓解率48.1%,6个月无进展生存率和总生存率分别为27.7%和49.6%;桥接组51.2%成功桥接至CAR-T,桥接联合成功CAR-T的6个月总生存率77.9%。

要点

  • pola-BR在真实世界挽救治疗中最佳总缓解率48.1%,6个月OS 49.6%。
  • 桥接组51.2%成功桥接至CAR-T,桥接联合成功CAR-T的6个月OS达77.9%。
  • 无化疗骨架的pola-利妥昔单抗总缓解率高达40%,可作为不适合化疗患者的替代选择。

核心结论

  • pola可作为复发或难治性大B细胞淋巴瘤有效的挽救和桥接治疗。

研究设计与样本

  • 回顾性分析德国26个中心105例接受pola-BR治疗的大B细胞淋巴瘤患者,来自国家同情用药计划。
  • 挽救和桥接队列患者既往中位治疗线数均为3线。

主要发现

  • 挽救队列最佳总缓解率为48.1%,6个月无进展生存率和总生存率分别为27.7%和49.6%。
  • 桥接队列中51.2%的患者成功桥接至计划的CAR-T治疗。
  • pola桥接联合成功CAR-T治疗从pola起始计算的6个月总生存率为77.9%。
  • 无化疗骨架的pola-利妥昔单抗总缓解率高达40%。
  • 12例既往CAR-T治疗失败患者中7例对含pola方案有应答。

临床怎么用

  • pola-BR可用于复发或难治性大B细胞淋巴瘤的挽救治疗。
  • pola可用于拟行CAR-T或异基因造血干细胞移植患者的桥接治疗。
  • 无化疗骨架的pola-利妥昔单抗可作为不适合化疗患者的替代选择。

局限性

  • 本研究为回顾性分析,来自同情用药计划,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Liebers N, Duell J, Fitzgerald D, et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021. PMID: 34196677. doi:10.1182/bloodadvances.2020004155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。